Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FQPY6
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $10,485
Award facts
- Contract value 100% obligated
- $10,484.64 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $10,484.64 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml autoinjector units. The delivery order, issued on December 30, 2025, with an ultimate completion date of January 22, 2026, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This award falls under DMS Pharmaceutical Group's broader Indefinite Delivery Contract with DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy established to support Department of Defense pharmaceutical supply needs globally.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, leveraging its small business status and comprehensive product portfolio spanning branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals. The company's primary IDC under the PPV-G GEN V program, valued at $499,999,999 through December 31, 2036, positions it as one of multiple regional prime vendor contractors authorized to issue firm fixed-price delivery orders for recurring medical supply needs across military healthcare facilities worldwide. This delivery order for Xolair, an immunosuppressant biologic agent, exemplifies the specialized pharmaceutical requirements DMS Pharmaceutical Group fulfills as part of its role supporting Department of Defense healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FQPY6?
SPE2DR26FQPY6 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 30, 2025.
How much is contract SPE2DR26FQPY6 worth?
The government has obligated $10,485 on SPE2DR26FQPY6.
Is contract SPE2DR26FQPY6 an order under another contract?
Yes. SPE2DR26FQPY6 is a delivery order under SPE2DR25D9331, an indefinite delivery contract.
Was contract SPE2DR26FQPY6 competed?
The extent of competition for SPE2DR26FQPY6 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award